Pmc54 Treatment Satisfaction Instruments for Different Purposes During a Product's Lifecycle—keeping the End in Mind

Rofail, Diana; Regnault, Antoine; Taylor, F. W.; Filonenko, Anna

doi:10.1016/s1098-3015(11)72337-3

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in keeping with other findings among patients with schizophrenia, 4,10 and further buttresses the position of Adelufosi et al, who posited that nonadherence to medication is rampant among patients with schizophrenia. 32 Medication non-adherence has been reported to be predicted by patient's subjective response and attitude towards antipsychotics, [33][34][35] which could have also been the case in this current study even though this was not assessed. The high rate of non-adherence found in this present study is also consistent with that reported by Valenstein et al, in their retrospective review of antipsychotic adherence over time among 34,128 patients receiving treatment for schizophrenia, where they found that about 61% of their study participants were poorly compliant to medication.…”

Section: Correlation Between Medication Adherence and Clinico-demogramentioning

confidence: 66%

Medication adherence among Nigerians with schizophrenia: correlation between clinico-demographic factors and quality of life

et al. 2017

View full text Add to dashboard Cite

Medication adherence contributes significantly to symptom remission, recovery and wellbeing in mental illnesses. We evaluated how medication adherence correlates with clinico-demographic factors and quality of life (QoL) in a sample of Nigerians with schizophrenia. This descriptive cross-sectional study involved 160 randomly selected participants with confirmed diagnosis of schizophrenia based on MINI International Neuropsychiatric Interview. Data on socio-demographic and clinical characteristics of participants were collected with a questionnaire. Medication adherence was assessed with Morisky Medication Adherence Questionnaire, and participants completed the World Health Organization Quality of Life Scale-BREF. The mean age of participants was 38.54 (±11.30) years, and all the participants were on antipsychotics, but only 45% were adherent to their medication. Out of all the participants, 45 (28.2%) considered their overall QoL to be good, 97 (60.6%) considered theirs to be fair, while 18 (11.2%) reported poor QoL. Medication non-adherence correlated negatively with good QoL across multiple dimensions including overall QoL (r=−0.175), health satisfaction (r=-0.161), physical (r=-0.186) and psychological domain (r=-0.175). Again, participant's age (r=−0.190) and age of onset of illness (r=-0.172) correlated negatively with medication non-adherence, and a trend towards relapse delay with medication adherence was also observed (r=-0.155). The effect size of these correlations were however small. Our findings suggest a link between medication adherence and QoL in schizophrenia, such that strategy that addresses medication non-adherence and its determinants may have potential benefits on wellbeing. Further hypotheses-driven studies are desirable.

show abstract

Section: Correlation Between Medication Adherence and Clinico-demogramentioning

confidence: 66%

Medication adherence among Nigerians with schizophrenia: correlation between clinico-demographic factors and quality of life

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We also assessed satisfaction with treatment in patients with RA. Satisfaction with treatment is increasingly recognized as an important and sensitive measure for treatment differentiation 13–15 . In our study, the patients without CSS group were more satisfied with treatment than were the patients with CSS group, and CSI scores were among the factors affecting patient satisfaction.…”

Section: Discussionmentioning

confidence: 58%

“…Satisfaction with treatment is increasingly recognized as an important and sensitive measure for treatment differentiation. [13][14][15] In our study, the patients without CSS group were more satisfied with treatment than were the patients with CSS group, and CSI scores were among the factors affecting patient satisfaction. Factors previously reported to affect satisfaction with RA treatment have included reduction of DAS28-ESR, pain, improvement in physical function, concomitant therapy with >5 mg of glucocorticoids per day and seropositivity for RA.…”

Section: Discussionmentioning

confidence: 95%

Central sensitivity syndrome affects the disease activity index and treatment satisfaction in patients with rheumatoid arthritis

Seki,

Imagama,

Seki

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimMany rheumatoid arthritis (RA) patients prioritize pain improvement in treatment. As pain can result from various causes, including noninflammatory factors such as central sensitivity syndrome (CSS), we hypothesized that CSS might impact treatment satisfaction. In this cross‐sectional study, we assessed the CSS effects on clinical disease activity and treatment satisfaction in RA patients.MethodsIn total, 220 consecutive RA patients receiving long‐term follow‐up were evaluated for clinical disease activity and treatment satisfaction. CSS was evaluated using the Central Sensitization Inventory (CSI). An overall score of ≥40 indicates the presence of CSS. We queried “How satisfied are you with your treatment?”; answers included (a) very satisfied, (b) satisfied, (c) not satisfied, or (d) very dissatisfied. For univariate analysis, we condensed these answers into “dissatisfied” or “satisfied.” We also evaluated treatment satisfaction using the visual analog scale (VAS), with scores ranging from 0 mm (very dissatisfied) to 100 mm (very satisfied).ResultsOf the 220 patients, 17 (7.7%) were classified as having CSS. CSI score was significantly correlated with the clinical disease activity index (CDAI; r = .322, p < .01) and treatment satisfaction (r = −.336, p < .01). Regarding treatment satisfaction, univariate analysis revealed that patient global assessment (PtGA), pain VAS, Health Assessment Questionnaire‐Disability Index (HAQ‐DI), Disease Activity Score in 28 joints with C‐reactive protein, CDAI, and CSI scores of patients who were satisfied with treatment differed significantly from those of dissatisfied patients. Multivariate analysis revealed that CSI, PtGA, and HAQ‐DI scores were associated with treatment satisfaction.ConclusionIn RA patients, CSS may affect the disease activity index and reduce treatment satisfaction.

show abstract

“…Background: Employees with inflammatory arthritis (IA) face restrictions in work performance from early onset of the disease, even with the improved medication regimes (1)(2). Little is known about the specifics of work adaptations and whether the workers involved experience the adaptations as successful (3).…”

mentioning

confidence: 99%

“…It comprises 7 domains that are evaluated as continuous variables from 0 (best) to 10 (worst). [1,2] Objectives: To define/identify cut-off values for disease activity states and improvement scores in order to present results at the individual level (e.g. patient in acceptable state, improved patient).…”

mentioning

confidence: 99%

SAT0474 Differences of clinical and ultrasound (US) remission in rheumatoid arthritis (RA) depend on the stringency of the us methodology

et al. 2013

View full text Add to dashboard Cite

Background Progression of joint damage in RA occurs primarily in joints that are clinically swollen, and repair is seen only in joints with no clinical swelling.1;2 On the other hand, joints exhibiting US but not clinical swelling may progress radiologically despite clinical remission.3 This discrepancy requires elucidation to understand the value of clinical compared with US joint assessment, since except for histology, there is no true gold standard for US joint activity. Objectives To evaluate the differences in number of clinically and US active joints in RA, with special regards to the impact of US definitions of activity. Methods We performed US imaging of 22 joints of the hands of RA patients in clinical remission (CDAI≤2.8). Each joint was assessed for grey scale synovial hypertrophy (GSSH; 0=no hypertrophy; 1=hypertrophy) and power Doppler (PD) signal (0= no hyperaemia, 1= mild, 2=moderate, 3=marked). We investigated the sensitivity and specificity of clinically swollen joints (SJC) for presence of US changes and repeated this analysis using different cut points and combinations of US definitions. We further assessed changes of CDAI if clinical SJC were replaced by US active joints. Results Of the 58 patients in clinical remission, 96.6% had GSSH and 93.1% had positive PD signals. The sensitivity and specificity of clinical SJC for any US abnormality (GSSH>0 or PD>0) was 1.7% and 100%, respectively. When we used more stringent definitions of US activity (GSSH>0 & PD=3), these values changed to 22.2% and 99%. Replacing clinical by US counts in the calculation of CDAI, the US CDAI values approached the clinical CDAI with increasing stringency of the definition used (Fig.). In fact, the most stringent definition (GSSH>0 & PD=3) revealed identical average values as seen in the clinical CDAI. Conclusions Low PD signals increase the numbers of patients classified as having active joints and lead to a poor sensitivity of clinical assessment in comparison to US assessment. When the PD signal is combined with assessment of GSSH, or the strength of the PD signal is considered, the differences decrease, particularly when looking at their impact on composite indices. The relevance of this finding will have to be tested in relation to radiographic progression of joint damage. References Klarenbeek NB et al. ARD 2010; 69(12):2107-2113. Lukas C et al. ARD 2010; 69(5):851-855. Brown AK et al. Arthritis Rheum 2008; 58(10):2958-2967. Disclosure of Interest None Declared

show abstract

Pmc54 Treatment Satisfaction Instruments for Different Purposes During a Product's Lifecycle—keeping the End in Mind

Cited by 4 publications

References 0 publications

Medication adherence among Nigerians with schizophrenia: correlation between clinico-demographic factors and quality of life

Medication adherence among Nigerians with schizophrenia: correlation between clinico-demographic factors and quality of life

Central sensitivity syndrome affects the disease activity index and treatment satisfaction in patients with rheumatoid arthritis

SAT0474 Differences of clinical and ultrasound (US) remission in rheumatoid arthritis (RA) depend on the stringency of the us methodology

Contact Info

Product

Resources

About